vs
Citi Trends Inc（CTRN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Citi Trends Inc的季度营收约是再鼎医药的1.6倍（$197.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs 10.1%），Citi Trends Inc自由现金流更多（$767.0K vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -4.3%）
Citi Trends Inc是一家美国服装零售连锁品牌，主营折扣服饰商品，目标客群以非裔美国人为主，凭借高性价比的产品策略在美国本土折扣零售市场占据一席之地。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CTRN vs ZLAB — 直观对比
营收规模更大
CTRN
是对方的1.6倍
$127.1M
营收增速更快
ZLAB
高出7.1%
10.1%
自由现金流更多
CTRN
多$27.5M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-4.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.1M | $127.1M |
| 净利润 | $-6.9M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -3.7% | -54.6% |
| 净利率 | -3.5% | — |
| 营收同比 | 10.1% | 17.1% |
| 净利润同比 | 3.6% | — |
| 每股收益（稀释后） | $-0.86 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTRNZLAB
| Q4 25 | $197.1M | $127.1M | ||
| Q3 25 | $190.8M | $115.4M | ||
| Q2 25 | $201.7M | $109.1M | ||
| Q1 25 | $211.2M | $105.7M | ||
| Q4 24 | $179.1M | $108.5M | ||
| Q3 24 | $176.6M | $101.8M | ||
| Q2 24 | $186.3M | $100.1M | ||
| Q1 24 | $215.2M | $87.1M |
净利润CTRNZLAB
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $3.8M | $-36.0M | ||
| Q2 25 | $871.0K | $-40.7M | ||
| Q1 25 | $-14.2M | $-48.4M | ||
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $-18.4M | $-41.7M | ||
| Q2 24 | $-3.4M | $-80.3M | ||
| Q1 24 | $3.6M | $-53.5M |
毛利率CTRNZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CTRNZLAB
| Q4 25 | -3.7% | -54.6% | ||
| Q3 25 | 1.8% | -42.3% | ||
| Q2 25 | 0.2% | -50.3% | ||
| Q1 25 | 0.6% | -53.3% | ||
| Q4 24 | -4.9% | -62.6% | ||
| Q3 24 | -14.1% | -66.6% | ||
| Q2 24 | -3.7% | -76.0% | ||
| Q1 24 | 1.8% | -80.7% |
净利率CTRNZLAB
| Q4 25 | -3.5% | — | ||
| Q3 25 | 2.0% | -31.2% | ||
| Q2 25 | 0.4% | -37.3% | ||
| Q1 25 | -6.7% | -45.8% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | -10.4% | -40.9% | ||
| Q2 24 | -1.8% | -80.2% | ||
| Q1 24 | 1.7% | -61.4% |
每股收益（稀释后）CTRNZLAB
| Q4 25 | $-0.86 | $-0.05 | ||
| Q3 25 | $0.46 | $-0.03 | ||
| Q2 25 | $0.11 | $-0.04 | ||
| Q1 25 | $-1.70 | $-0.04 | ||
| Q4 24 | $-0.86 | $-0.09 | ||
| Q3 24 | $-2.21 | $-0.04 | ||
| Q2 24 | $-0.42 | $-0.08 | ||
| Q1 24 | $0.43 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $107.8M | $715.5M |
| 总资产 | $464.3M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTRNZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
股东权益CTRNZLAB
| Q4 25 | $107.8M | $715.5M | ||
| Q3 25 | $113.2M | $759.9M | ||
| Q2 25 | $108.6M | $791.7M | ||
| Q1 25 | $113.2M | $810.8M | ||
| Q4 24 | $130.3M | $840.9M | ||
| Q3 24 | $136.6M | $667.7M | ||
| Q2 24 | $154.8M | $704.2M | ||
| Q1 24 | $157.7M | $762.2M |
总资产CTRNZLAB
| Q4 25 | $464.3M | $1.2B | ||
| Q3 25 | $457.4M | $1.2B | ||
| Q2 25 | $437.4M | $1.2B | ||
| Q1 25 | $462.8M | $1.2B | ||
| Q4 24 | $467.1M | $1.2B | ||
| Q3 24 | $506.7M | $985.3M | ||
| Q2 24 | $484.1M | $987.4M | ||
| Q1 24 | $518.7M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $767.0K | $-26.7M |
| 自由现金流率自由现金流/营收 | 0.4% | -21.0% |
| 资本支出强度资本支出/营收 | 4.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $11.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CTRNZLAB
| Q4 25 | $8.6M | $-26.0M | ||
| Q3 25 | $3.9M | $-32.0M | ||
| Q2 25 | $-11.0M | $-31.0M | ||
| Q1 25 | $28.5M | $-61.7M | ||
| Q4 24 | $-18.4M | $-55.8M | ||
| Q3 24 | $5.6M | $-26.8M | ||
| Q2 24 | $-19.6M | $-42.2M | ||
| Q1 24 | $23.3M | $-90.1M |
自由现金流CTRNZLAB
| Q4 25 | $767.0K | $-26.7M | ||
| Q3 25 | $-1.7M | $-35.0M | ||
| Q2 25 | $-13.1M | $-33.9M | ||
| Q1 25 | $26.0M | $-63.2M | ||
| Q4 24 | $-20.4M | $-58.4M | ||
| Q3 24 | $1.7M | $-28.2M | ||
| Q2 24 | $-21.2M | $-42.9M | ||
| Q1 24 | $20.0M | $-91.1M |
自由现金流率CTRNZLAB
| Q4 25 | 0.4% | -21.0% | ||
| Q3 25 | -0.9% | -30.4% | ||
| Q2 25 | -6.5% | -31.1% | ||
| Q1 25 | 12.3% | -59.9% | ||
| Q4 24 | -11.4% | -53.8% | ||
| Q3 24 | 0.9% | -27.7% | ||
| Q2 24 | -11.4% | -42.9% | ||
| Q1 24 | 9.3% | -104.5% |
资本支出强度CTRNZLAB
| Q4 25 | 4.0% | 0.5% | ||
| Q3 25 | 2.9% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 1.2% | 1.5% | ||
| Q4 24 | 1.1% | 2.4% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 0.9% | 0.7% | ||
| Q1 24 | 1.5% | 1.1% |
现金转化率CTRNZLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | -12.59× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.56× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTRN
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
